Clinical trials: Seizures Disorders
Epilepsy, Lennox-Gastaut Syndrome
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
- Trial name
- GWPCARE4 (NCT02224690)
- Testing
- GWP42003-P 20 mg/kg/day Dose
- Where
- 24 sites in United States, Netherlands and 1 more
- Volunteers
- 171 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy, Idiopathic Generalized Epilepsy
RNS System NAUTILUS Study
To demonstrate that the RNS System for thalamic stimulation is safe and effective as an adjunctive therapy for the reduction of primary generalized seizures in individuals 12 years of age or older who have drug-resistant…
- Conditions
- Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure
- Trial name
- NAUTILUS (NCT05147571)
- Testing
- Responsive stimulation
- Where
- 23 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroPace
Epilepsy
P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.
In up to 1 out of 3 patients with epilepsy, seizures continue to occur despite the use of one or more antiepileptic medications.
- Trial name
- NCT00524134
- Testing
- Carvedilol-CR
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Epilepsy, Seizures, Epileptic
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
- Trial name
- NCT05518578
- Testing
- SPN-817
- Where
- 10 sites in United States, Australia
- Volunteers
- 60 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Neonatal Seizure, Neonatal Encephalopathy
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
The main purpose of this study is to determine the maximum safe tolerated dose of LEV in the treatment of neonatal seizures. Our hypothesis is that optimal dosing of Levetiracetam (LEV) to treat neonatal seizures is significantly…
- Conditions
- Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy, Seizure Newborn
- Trial name
- NEOLEV3 (NCT05610085)
- Testing
- Levetiracetam Injection, Phenobarbital Sodium Injection
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 133 people
- Sponsor
- University of California, San Diego
Neonatal Convulsions
Incidence of Metabolic Disorders in Neonatal Convulsions
Describe the incidence of metabolic disorders in neonatal convulsions affecting neonates at NICU Describe types of metabolic disorders causing neonatal convulsions
- Trial name
- NCT06108778
- Testing
- MRI
- Volunteers
- 115 people
- Sponsor
- Assiut University
Focal Seizure
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
- Trial name
- POWER1 (NCT06999902)
- Testing
- 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
- Where
- 69 sites in United States, Brazil and 5 more
- Volunteers
- 255 people
- Sponsor
- Praxis Precision Medicines
Eclampsia, Seizures
Comparing Intravenous and Intramuscular Magnesium Sulphate for Preventing Seizure Recurrence in Women With Eclampsia
The goal of this clinical study is to learn whether the way we give magnesium sulphate-into a vein (intravenous, IV) versus into a muscle (intramuscular, IM)-affects how often women with eclampsia have repeat seizures.
- Conditions
- Eclampsia, Seizures, Pregnancy
- Trial name
- NCT06997575
- Testing
- Magnesium Sulphate infusion, Magnesium sulphate intramuscular
- Where
- Pakistan
- Volunteers
- 200 people
- Sponsor
- Nishtar Medical University
Anxiety Disorder, Head Injury
Neuropsychological Evaluation of Psychiatric and Neurological Patients
This study will allow researchers to use various types of tests to evaluate cognitive and sensory functions. These tests, referred to as "batteries" will evaluate attention, executive functions, general intellectual functioning…
- Conditions
- Anxiety Disorder, Head Injury, Mood Disorder, Schizophrenia
- Trial name
- NCT00001192
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 4,300 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Drug Resistant Epilepsy, Epilepsy
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in…
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure
- Trial name
- NCT06388707
- Testing
- NaviFUS System
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NaviFUS Corporation
Major Depressive Episode (MDE), Unipolar Disorder
Evaluating the Therapeutic Potential of Focal Electrically Administered Seizure Therapy (FEAST) in the Treatment of Depression: A Multicenter Randomized Clinical Trial
A significant proportion of patients remain resistant to antidepressant therapies, even when treatment is well managed. Electroconvulsive therapy (ECT) is a well-established method for treating certain severe and resistant…
- Conditions
- Major Depressive Episode (MDE), Unipolar Disorder, Bipolar 1 Disorder
- Trial name
- FEAST-AFT (NCT07857122)
- Testing
- Stimulation by the Sigma ECT/FEAST device, Stimulation by Sigmastim ECT 200J device administered in right unilateral (RUL), Stimulation by Sigmastim ECT 200J device administered in bilateral (BT)
- Where
- 5 sites in France, Monaco
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier St Anne
Epilepsy, Seizures
University of Alabama at Birmingham (UAB) Pediatric CBD Program
The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.
- Trial name
- NCT02695537
- Testing
- Epidiolex
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Alabama at Birmingham
Status Epilepticus
Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus
Since there is a significant degree of variability in the results of previous studies and there exists a thirst for local data regarding this topic, the current study was planned, with the objective of comparing the efficacy of…
- Trial name
- NCT07052136
- Testing
- Levetiracetam, Valproic acid
- Where
- Pakistan
- Volunteers
- 138 people
- Sponsor
- RESnTEC, Institute of Research
Partial Seizure Disorder, Epilepsy
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
- Conditions
- Partial Seizure Disorder, Epilepsy, Seizures
- Trial name
- NCT00113815
- Testing
- topiramate
- Where
- 94 sites in United States, Argentina and 21 more
- Volunteers
- 118 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Convulsive Seizures
The Pattern of Pediatric Seizures at Al-Arish Central Hospital - North Sinai
This study will be carried to: 1. Describe the pattern of seizures among cases admitted to Pediatric department at Al-Arish central hospital in North Sinai and compare results with national and international similar studies . 2.
- Trial name
- NCT03374384
- Testing
- No drug intervention
- Volunteers
- 100 people
- Sponsor
- Ehsan M saied
Cardiovascular Diseases, Cardiovascular Diseases Risk
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways
Cor360 is an observational study evaluating whether extended wearable electrocardiogram (ECG) data can support broad-spectrum cardiac phenotyping and risk assessment beyond conventional single-purpose ambulatory rhythm…
- Conditions
- Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities
- Trial name
- Cor360 (NCT07775976)
- Testing
- COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Partial Epilepsy
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy
The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy…
- Trial name
- NCT00957047
- Testing
- eslicarbazepine acetate, ESL - Part II
- Where
- Portugal
- Volunteers
- 395 people
- Sponsor
- Bial - Portela C S.A.
Sensorineural Hearing Loss, Bilateral
Comparison of Speech Understanding Between Tonotopy-based Fitting and Setting Based on Evolutionary Algorithms
Main objective: Compare speech recognition in noise with tonotopic setting (FS4T) and with tonotopic fitting modified by evolutionary algorithm (EAFS4T) in adult patients implanted for 6 months or more with a MED-EL cochlear…
- Trial name
- NCT06737185
- Testing
- EAFS4T: modification with evolutionary algorithm of tonotopic-based fitting
- Where
- France
- Volunteers
- 22 people
- Sponsor
- MED-EL Elektromedizinische Geräte GmbH
Epilepsy, Seizure
AI-Based Mobile Intervention on Medication Non-Adherence and Transition
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and…
- Trial name
- NCT07445074
- Testing
- Medilepsy® Chatbot AI-Enhanced, Medilepsy® Chatbot Standard
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Central Florida
Mild to Moderate Sensorineural Hearing Loss
Study of SelfFit Mobile Medical App for Hearing Loss Diagnostics and Hearing Device Fitting / Fine Tuning
The purpose of this clinical study is to validate the comparability of prescription formula fitting of hearing aids based on full diagnostic audiometry and SelfFit interactive fitting of hearing aids based on hearing loss…
- Trial name
- SelfFit (NCT01877317)
- Testing
- SelfFit adjusted hearing device
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Two Pi Signalprocessing Applications GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.